The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
Public ClinicalTrials.gov record NCT00427219. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.
Study identification
- NCT ID
- NCT00427219
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 23, 2007 (Actual)
- Primary completion
- Feb 27, 2008 (Actual)
- Completion
- Feb 27, 2008 (Actual)
- Last update posted
- Oct 15, 2021
2007 – 2008
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Donald Gleason, MD | Tucson | Arizona | 85712 | — |
| Jay Young, MD | Laguna Hills | California | 92653 | — |
| Alexander Gershman, MD | Los Angeles | California | 90048 | — |
| Stephen Auerbach, MD | Newport Beach | California | 92660 | — |
| Eugene Dula, MD | Tarzana | California | 91356 | — |
| Joel Kaufman, MD | Aurora | Colorado | 80012 | — |
| Ira Klimberg, MD | Ocala | Florida | 34474 | — |
| Joseph Williams, MD | Meridian | Idaho | 83642 | — |
| Christopher Steidle, MD | Fort Wayne | Indiana | 46825 | — |
| Steven Bigg, MD | St Louis | Missouri | 63136 | — |
| Jed Kaminetsky, MD | New York | New York | 10016 | — |
| William Fitch, MD | San Antonio | Texas | 78229 | — |
| Gregg Eure, MD | Virginia Beach | Virginia | 23454 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00427219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2021 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00427219 live on ClinicalTrials.gov.